<code id='E440163897'></code><style id='E440163897'></style>
    • <acronym id='E440163897'></acronym>
      <center id='E440163897'><center id='E440163897'><tfoot id='E440163897'></tfoot></center><abbr id='E440163897'><dir id='E440163897'><tfoot id='E440163897'></tfoot><noframes id='E440163897'>

    • <optgroup id='E440163897'><strike id='E440163897'><sup id='E440163897'></sup></strike><code id='E440163897'></code></optgroup>
        1. <b id='E440163897'><label id='E440163897'><select id='E440163897'><dt id='E440163897'><span id='E440163897'></span></dt></select></label></b><u id='E440163897'></u>
          <i id='E440163897'><strike id='E440163897'><tt id='E440163897'><pre id='E440163897'></pre></tt></strike></i>

          
          WSS
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge